NGL Fine Chem Faces Valuation Shift Amid Declining Profitability and Performance Challenges

NGL Fine Chem, a microcap company in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. The revision in its score reflects a shift in valuation metrics, indicating a transition from a previously favorable assessment to a more cautious stance.
Key financial indicators reveal that the company's price-to-earnings (PE) ratio stands at 36.57, while the price-to-book value is noted at 2.70. The enterprise value to EBITDA ratio is recorded at 23.83, and the enterprise value to EBIT is at 38.76. These metrics suggest a valuation that may not align with the company's recent performance trends.

In terms of profitability, the return on capital employed (ROCE) is reported at 6.85%, and the return on equity (ROE) is at 7.38%. The company has faced challenges, with a significant decline in profit after tax (PAT) and profit before tax (PBT) in the latest quarter. Additionally, the stock has shown a negative return of -45.39% over the past year, underperforming against broader market indices.

Overall, the adjustment in evaluation for NGL Fine Chem highlights the complexities of its financial landscape, influenced by both short-term performance and long-term growth prospects.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.